PPARs: A Double-Edged Sword in Cancer Therapy?

by Dipak Panigrahy, Arja Kaipainen, Mark W. Kieran, Sui Huang
Published 2008-01-01

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

by Arja Kaipainen, Mark W Kieran, Sui Huang, Catherine Butterfield, Diane Bielenberg, Gustavo Mostoslavsky, Richard Mulligan, Judah Folkman, Dipak Panigrahy
Published 2007-01-01

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

by Michael D. Nyquist, Alexandra Corella, Ilsa Coleman, Navonil De Sarkar, Arja Kaipainen, Gavin Ha, Roman Gulati, Lisa Ang, Payel Chatterjee, Jared Lucas, Colin Pritchard, Gail Risbridger, John Isaacs, Bruce Montgomery, Colm Morrissey, Eva Corey, Peter S. Nelson
Published 2020-05-01

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

by Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, Justin Hwang, Sheng Yu Ku, Rand Arafeh, Taylor Arnoff, Supreet Agarwal, Connor Bell, Edward O’Connor, Xintao Qiu, Sarah Abou Alaiwi, Rosario I. Corona, Marcos A. S. Fonseca, Claudia Giambartolomei, Paloma Cejas, Klothilda Lim, Monica He, Anjali Sheahan, Amin Nassar, Jacob E. Berchuck, Lisha Brown, Holly M. Nguyen, Ilsa M. Coleman, Arja Kaipainen, Navonil De Sarkar, Peter S. Nelson, Colm Morrissey, Keegan Korthauer, Mark M. Pomerantz, Leigh Ellis, Bogdan Pasaniuc, Kate Lawrenson, Kathleen Kelly, Amina Zoubeidi, William C. Hahn, Himisha Beltran, Henry W. Long, Myles Brown, Eva Corey, Matthew L. Freedman
Published 2021-03-01